Prevalence and Clinical Significance of Potential Drug-Drug Interactions in Hospitalized Pediatric Oncology Patients: A Prospective Pharmacoepidemiologic Study.

ABSTRACT:

Background

Drug-drug interactions (DDIs) are frequent and potentially harmful in pediatric cancer patients due to polypharmacy and complex chemotherapy regimens. However, data on DDIs in hospitalized pediatric oncology patients remain limited, particularly in Middle Eastern settings.

Methods

In this prospective study, we analyzed prescriptions for hospitalized pediatric oncology patients in Iran to assess the prevalence, severity, and nature of potential DDIs (PDDIs). Chemotherapy and supportive medications were analyzed using two validated databases (Lexi-Interact™ and Drugs.com™) between November 2019 and June 2020.

Results

Of 80 patients (median age 8.9 years), 21.2% had at least one documented PDDI. We identified 197 total PDDIs involving 42 unique drug pairs. The most common DDIs included acetaminophen and granisetron (severity rating: moderate). Methotrexate and vincristine were the most frequent antineoplastic DDI pair. Methotrexate alone accounted for 156 interactions.

Conclusions

This is the first prospective study from Iran-and the largest in the region-investigating PDDIs in pediatric oncology. The dual-database screening approach improved PDDI detection. Clinical teams should routinely evaluate medication profiles in pediatric cancer patients to minimize avoidable harms from DDIs.

SUBMITTER: Zekavat OR 

PROVIDER: S-EPMC12469098 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature